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Abstract
Background: Several fMRI studies found hyperactivity in the hippocampus during pattern separation tasks in
patients with Mild Cognitive Impairment (MCI; a prodromal stage of Alzheimer’s disease). This was associated with
memory deficits, subsequent cognitive decline, and faster clinical progression. A reduction of hippocampal
hyperactivity with an antiepileptic drug improved memory performance. Pharmacological interventions, however,
entail the risk of side effects. An alternative approach may be real-time fMRI neurofeedback, during which
individuals learn to control region-specific brain activity. In the current project we aim to test the potential of
neurofeedback to reduce hippocampal hyperactivity and thereby improve memory performance.
Methods: In a single-blind parallel-group study, we will randomize n = 84 individuals (n = 42 patients with MCI, n =
42 healthy elderly volunteers) to one of two groups receiving feedback from either the hippocampus or a
functionally independent region. Percent signal change of the hemodynamic response within the respective target
region will be displayed to the participant with a thermometer icon. We hypothesize that only feedback from the
hippocampus will decrease hippocampal hyperactivity during pattern separation and thereby improve memory
performance.
Discussion: Results of this study will reveal whether real-time fMRI neurofeedback is able to reduce hippocampal
hyperactivity and thereby improve memory performance. In addition, the results of this study may identify
predictors of successful neurofeedback as well as the most successful regulation strategies.
Trial registration: The study has been registered with clinicaltrials.gov on the 16th of July 2019 (trial identifier:
NCT04020744).
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Background
Dementia due to Alzheimer’s disease (AD) is a neurode-
generative disorder associated with cognitive and func-
tional decline. The underlying pathological process
begins at least a decade before any clinical symptoms [1]
and is characterized by neuronal cell death, extracellular
deposits of amyloid-ß (Aβ) and intracellular formation
of fibrillary aggregates of abnormally phosphorylated tau
[2]. Activity in the hippocampus, as measured by func-
tional magnetic resonance imaging (fMRI), is among the
key emerging neuroimaging markers that allow an im-
proved AD risk prediction [3]. In AD, hippocampal ac-
tivity is typically decreased during memory tasks due to
hippocampal atrophy. However, several fMRI studies in
the prodromal stage of AD (i.e., in Mild Cognitive Im-
pairment, MCI) have found increased hippocampal ac-
tivity during memory tasks that was associated with
memory deficits, subsequent cognitive decline and faster
clinical progression [4–6]. Pattern separation, a process
thought to critically depend on the hippocampus, has
been particularly used as a task to show increased hippo-
campal activity in patients with MCI [7, 8]. Pharmaco-
logical treatment of hyperactivity in patients with MCI,
or in mice with increased levels of Aβ, significantly re-
duced activity in the hippocampus and improved mem-
ory performance in pattern separation tasks [7].
Although one may expect that reducing brain activation
in a given area will lead to a drop in performance, there
is emerging evidence that hyperactivity in the hippocam-
pus has a negative, rather than a positive, impact on cog-
nition [9]. Thus, reducing excess hippocampal activity
may present a promising therapeutic target. Pharmaco-
logical interventions, however, are prone to side effects
such as headache, diarrhoea, or sleep disturbances. In
addition, an elderly population is likely to be on other
medication so - apart from the possible side effects -
drug interaction may be a problem. An alternative ap-
proach may be real-time fMRI neurofeedback. With
real-time fMRI neurofeedback, participants train to vol-
untarily ‘control’ region specific brain activity [10, 11].
The training is accomplished by continuously measuring
brain activity in real-time, and providing feedback to the
participant about the ongoing activity in the targeted
brain area [11].
The current study aims to test whether real-time fMRI
neurofeedback is capable of reducing hippocampal
hyperactivity in patients with MCI and, in addition,
whether the reduction of hyperactivity will be associated
with an improvement in memory performance. Compar-
able to previous studies, we will deploy pattern separ-
ation tasks to assess hippocampal activity as well as
memory performance (e.g., [7, 8]). As there is evidence
for an association between Aβ and hippocampal hyper-
activity [9], we will determine Aβ levels in blood. In
addition, we will examine variables that may predict
neurofeedback success and identify the most successful
regulation strategies.
Methods
Participants eligibility and recruitment
Eligible participants will be between 60 and 80 years of
age, fluent in German, with normal or corrected-to-
normal vision. Patients with MCI will be included if
their memory performance is below age-, gender-, and
education-adjusted norms as assessed with the delayed
recall score of a list of words included in the CERAD
neuropsychological battery (CERAD [12];). Other cogni-
tive functions may also be below the norm but an im-
pairment in memory performance is mandatory since
this subgroup is particularly prone to hippocampal
hyperactivity [7]. In addition, they will need to a) report
a cognitive complaint, b) show no impairment in activ-
ities of daily living, c) show no dementia but d) show
signs of neuronal injury (i.e., atrophy in the hippocam-
pus or the medial temporal lobe) according to updated
criteria [13]. This will provide intermediate certainty that
MCI will develop into AD [13].
Healthy elderly participants will be included if their
Montreal Cognitive Assessment (MoCA) score is ≥26
[12] and their Geriatric Depression Score (GDS) is ≤5
[14]. All participants will need to give written informed
consent before the study. Exclusion criteria would be
major psychiatric, neurological, or medical disorders or
a history of epilepsy or severe head injury, current or
life-time substance abuse, contra-indications to MRI, or
psychoactive medication.
We will recruit healthy elderly volunteers via news-
paper advertisements. Patients with MCI due to AD
pathology will be recruited from the local memory clinic
where they will receive their diagnosis. The study has
been approved by the Ethics Committee of the Canton
of Bern (2019–00958) and will be conducted in accord-
ance with the declaration of Helsinki. Recruitment will
continue until the required number of participants is
reached.
Screening assessment and group allocation
We will screen participants during a telephone call (and
only invite them to participate in the study if deemed
eligible). Those who will meet inclusion criteria will be
randomly assigned to the experimental group or the
control group. The experimental group will downregu-
late activity in the hippocampus; the control group will
downregulate activity in the intraparietal sulcus, a region
that plays a key role in spatial attention [15] but not in
pattern separation or memory. The participants will not
be informed which area they will need to regulate (i.e.,
from which area they will receive feedback). Thus, we
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will apply a single-blind, randomized, parallel-group de-
sign. Choosing an alternative region in a control group
will ensure physiological specificity to ensure that only
the regulation of hippocampal activity (and not the regu-
lation of any other brain region) will lead to a reduction
of hippocampal hyperactivity and, in consequence, to an
improvement in memory performance [16]. Group allo-
cation will be conducted by the Clinical Trials Unit Bern
with computer-generated random numbers, stratified for
age, gender, and group status (i.e., MCI or healthy
volunteers).
Study procedure
The study will consist of seven appointments, five of
which will take place in short succession with an add-
itional two after 6 and 12 months (Fig. 1). We will first
apply two baseline assessments (behavioural data
followed by MRI data), two intervention sessions (i.e.,
the neurofeedback training), and one post-intervention
(Fig. 1). We chose to split the two baseline assessments
(i.e., behavioural data assessment and MR imaging) to
avoid fatigue. All sessions will have approximately 1
week in-between and will last between 40 and 80min.
Six and 12 months after the post-intervention, we will
apply follow-up assessments. Each of the assessments
will be described in detail below, and an overview can be
found in Table 1.
Baseline behavioural assessment
At the first baseline assessment, we will acquire behav-
ioural data (both with paper-and-pencil tasks and with
Delta 1.4.2 on a tablet) as well as draw blood. We will
start with drawing blood followed by cognitive screening
with the MoCA in healthy volunteers or the Cognitive
Functions Dementia battery (CFD) in patients with MCI
due to AD. Although cognitive functions have already
been evaluated during the diagnostic process in patients
with MCI, we chose to apply another evaluation to ac-
count differences in time from diagnosis and study par-
ticipation. Additionally, we will implement the Stroop
task as well as the Digit Span task. After cognitive
screening, we will employ several questionnaires, all of
which have been validated in German: Spontaneous Use
of Imagery Scale, Scale of Self-Efficacy, Neo Five-Factor
Inventory, and State Trait Anxiety Inventory. The ques-
tionnaires will assess mental imagery, self-efficacy, per-
sonality traits, as well as anxiety all of which may
influence the ability to regulate brain activity and/ or re-
spond to feedback. Variables from the questionnaires
will be used later for prediction analyses. We expect in
particular that participants who score high on mental
imagery as well as self-efficacy would benefit from the
intervention. Likewise, those with high scores on open-
ness and low scores on state/trait anxiety may be those
who learn fast from feedback. Blood will be drawn to de-
termine the apolipoprotein E (ApoE) genotype as well as
the genetic variant of the brain derived neurotrophic fac-
tor (BDNF). The ApoE genotype seems to influence hip-
pocampal activity [17, 18] and will, therefore, be
included as a covariate in our statistical model. Likewise,
we will include the BDNF genotype as it serves as a gen-
etic modifier of brain plasticity and, thus, may influence
the ability to learn from feedback. Finally, we will obtain
Aβ42 as well as Aβ42/40 levels from blood using Simoa
technology using methods established by the Neuro-
chemistry Lab Amsterdam University Medical Centres
Fig. 1 Study procedure. We will include n = 84 participants (n = 42 healthy elderly volunteers and n = 42 patients with Mild Cognitive
Impairment). They will receive fMRI neurofeedback twice (Intervention I and II), and behavioural and MRI data will be assessed before and after
the intervention. The figure has been designed by the authors
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[19]. Since hippocampal hyperactivity is particularly
present in those with increased Aβ (and vice versa), the
acquisition of Aβ is of specifal interest for this study.
Baseline MRI
MRI data will be collected with a 32-channel head coil
on a 3 Tesla Magnetom Prisma scanner (Siemens Med-
ical Systems, Erlangen, Germany) at the Translational
Imaging Center Bern. First, a T1-weighted structural
image is obtained using a magnetization-prepared 2
rapid acquisition gradient echoes (MP2RAGE) sequence
(176 slices, repetition time (TR) = 5000ms, echo time
(TE) = 2.98 ms, inversion time (TI) = 2500 ms, flip
angle = 5°, matrix = 240 × 256, voxel size = 1 × 1 × 1mm).
Next, task-related blood oxygenation-level dependent
data will be acquired using a T2*-weighted echo-planar
imaging (EPI) sequence. One thousand eighty volumes
will be collected during a pattern separation task (see
below); each volume will consist of 56 slices with 2.5
mm thickness (flip angle = 30 °, TR = 1000ms, TE = 37
ms, matrix size = 92 × 92, voxel size = 2.5 × 2.5 × 2.5 mm).
Finally, non-hemodynamic resonant saturation effects
will be assessed with a phase-cycled stimulus-induced
rotary saturation approach [20]. A spin-lock radiofre-
quency pulse set to 120 Hz will be used to sensitize im-
ages to a frequency in the range of oscillating neuronal
currents induced by epileptogenic tissue. Two T2*-
weighted EPI sequences (300 volumes, slice thickness =
5 mm, skip = 10mm, flip angle = 90 °, TR = 139.55 ms,
TE = 29.12 ms, matrix size = 64 × 64, voxel size = 3.3 ×
3.3 × 3.3 mm) will be acquired simultaneously. Later, T2*
effects will be separated from rotary saturation effects by
deconvolving spin-lock-off from spin-lock-on images.
Pattern separation task
We chose to apply a pattern separation task, as hippo-
campal hyperactivity has been found particularly with
this task in patients with MCI [7, 8]. The pattern separ-
ation task will be presented with PsychoPy (version 3.1
[21];). All participants will complete two runs of an ex-
plicit version of the task [22], during which coloured pic-
tures of objects will be presented. These objects can be
new (first presentations), repetitions of previously shown
objects (repetitions), objects similar to those previously
shown (lures), or new objects presented only once (foils;
Fig. 2). Participants will need to categorize each object
as either new, old, or similar. One run will include 200
stimuli, and each stimulus will be presented for 2 s with
0.5 s inter-stimulus interval. The 200 stimuli will include
40 foils, 40 repetitions, and 40 lures with an additional
40 of first presentations for repetitions and lures, re-
spectively. The order of object presentation will be ran-
domized for each participant. As in previous studies, the
contrast of interest for the definition of baseline hippo-
campal activity will be lures > foils [7].
Table 1 Schedule of assessments conducted during the study
Baseline I Baseline II Intervention I Intervention II Post-Intervention Follow-up I Follow-up II
Blood sample X X
Questionnaires
Scale of Self-Efficacy X
Spontaneous use of Imagery X
Neo-Five Factor Inventory X
State-Trait Anxiety Inventory X
Profile of Mood States X X
Positie and Negative Affect Schedule X X
Cognition
Montreal Cognitive Assessmenta X
Cognitive Functions Dementiab X
Stroop X
Digit Span X
Verbal Learning and Memory Test X X X X X X
MR Imaging
Structural MRI X X X
Functional MRI X X X
Neurofeedback X X
aIn healthy elderly volunteers
bIn patients with Mild Cognitive Impairment
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Neurofeedback setup
Approximately 1 week after baseline MRI, we will apply
the neurofeedback training on 2 days with 1 week in-
between. Each neurofeedback session will last about 60
min and will consist of five runs of training as well as
two transfer runs (one prior to the feedback runs and
another one directly following the feedback runs). The
transfer run will assess the innate ability to regulate ac-
tivity without feedback (first transfer run) or how much
of the learned ability can be maintained without feed-
back (final transfer run). Each run (i.e., transfer or train-
ing) will consist of baseline blocks and regulation blocks
(5:32 min in total) but only during training, feedback will
be provided (Fig. 3). The feedback signal will be calcu-
lated with OpenNFT [23]. We will use the same EPI se-
quence as during baseline MRI. All DICOM images will
be transferred directly from the imaging computer to a
laptop running OpenNFT. OpenNFT will process these
images in real-time (i.e., faster than image acquisition)
and estimate whole-brain activation maps using an in-
cremental general linear model (iGLM) algorithm. We
will apply intermittent feedback (i.e., feedback presented
after regulation as compared to during regulation), as
this was shown to be more effective than continuous
Fig. 2 Pattern separation task applied during fMRI. For each run, 200 different objects will be randomly presented for 2 s (0.5 s inter-stimulus
interval). The participants will need to decide whether an object is new, old, or similar. The figure has been designed by the authors with stimuli
illustrations from https://github.com/celstark/MST
Fig. 3 Neurofeedback setup. a The participants will see a slightly adapted version of the pattern separation task while they will need to
downregulate activity in one of two regions of interest. b The functional brain activity in this region of interest will be measured continuously
and sent to the laptop containing OpenNFT. c These data will be processed in real-time to estimate the percent signal change in the region of
interest, which will be sent to the presentation laptop. d The value of the percent signal change will then be presented to the participants with a
dynamic thermometer that changes colour from red (indicating increased activity) to green (indicating decreased activity). The figure has been
designed by the authors with stimuli illustrations from https://github.com/celstark/MST and icons from www.flaticon.com
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feedback in promoting self-modulation of brain activity
[24]. The feedback signal will be estimated based on
activity-levels in the respective region of interest (ROI)
as the percent signal change (PSC) between baseline and
regulation blocks. The PSC will be calculated as the
average of the spatial-temporal data obtained from
within the ROI. Further, OpenNFT will dynamically use
the average of the highest and lowest activity time points
of the acquired ROI data to estimate maximum and
minimum limits of scaling used to calculate the final
PSC value. The estimated feedback signal will be sent to
the presentation computer and then presented to the
participant using a thermometer icon (Fig. 3).
ROIs will be defined based on individual anatomical masks
created with the individual T1-weighted images collected
during baseline MRI. We will apply FreeSurfer (Linux-cen-
tos, v6.0.0, [25] to create individual ROIs and then co-
register them to the motion correction file used for online re-
alignment of the OpenNFT pre-processing pipeline.
Neurofeedback session
The neurofeedback task as well as the feedback will be
presented with PsychoPy (version 3.1, [21]). For each
session, we opted for a block design that includes four
repetitions. During the baseline condition, participants
will need to slowly count backwards from 100 for 30 s
(Fig. 4). During the regulation condition, a slightly
adapted version of the pattern separation task will be ap-
plied for 44 s. Again, the participants will be randomly
presented with objects. These will include six foils, six
lures and six first presentations of subsequent lures (i.e.,
18 objects in total). Again, each object will be presented
for 2 s with 0.5 s inter-stimulus interval (Fig. 4). In con-
trast to the fMRI task, however, the participants will not
need to respond in any way to these images but rather
try to downregulate activity. Previous research has
shown that a response from participants is not required
to induce hippocampal activity [26]. For the regulation
of brain activity, we decided to use an implicit approach,
which means that participants are told the goal would be
to modify the thermometer icon until the green colour
appears but we do not suggest explicit strategies for how
to achieve this goal (i.e., they will need to try different
mental strategies in order to find a strategy that works
best for them [27, 28]. Feedback on the success of the
regulation will be presented for 4 s. During the transfer
Fig. 4 Neurofeedback session. Each run will include four repetitions of baseline and regulation blocks, as well as the feedback presented using a
thermometer icon. The thermometer icon will be filled with colours ranging from red to green during training or will remain grey during transfer.
TR: Repetition time (1 TR = 2 s). The figure has been designed by the authors with stimuli illustrations from https://github.com/celstark/MST
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runs, the participants will see a thermometer icon with-
out feedback (Fig. 4).
Following the neurofeedback session, we will perform
behavioural testing outside the scanner using a word list
learning task (i.e., the VLMT [29];) that also probes
memory functions. Afterwards, we will conduct debrief-
ing of mental strategies. At the beginning and at the end
of each session, we will apply the Profile of mood states
(POMS [30];) and the Positive and Negative Affect
Schedule (PANAS [31];) to assess whether the change in
mood due to neurofeedback is similar for the control
group and the experimental group.
Post-intervention MRI
Approximately 1 week after the two neurofeedback ses-
sions, participants will undergo post-intervention MRI.
They will complete the fMRI pattern separation task that
they have completed during baseline MRI (with different
objects). In addition, we will again collect non-
hemodynamic resonant saturation effects [20].
Follow-up assessments
Approximately 6 and 12months after the intervention,
we will implement follow-up assessments. At the 6-
months follow-up, we will only acquire behavioural data
with the VLMT. At 12-months follow-up, we will apply
the VLMT, draw blood again to obtain amyloid levels,
and apply structural as well as functional MRI. For the
fMRI task, we will again examine pattern separation per-
formance (with different objects). In addition, partici-
pants will be examined using the MoCA (in healthy
controls) or the CFD (in patients with MCI) for a second
time.
Statistical analyses
The primary outcome is the change in hippocampal ac-
tivity as assessed with a pattern separation task during
fMRI before and after both neurofeedback sessions. For
the determination of intervention effects on hippocam-
pal activity, we will compute repeated measures ANOVA
with intervention (experimental vs. control group) and
group (healthy volunteers vs. patients with MCI due to
AD) as between-subject factors. We will include the gen-
etic variants of ApoE and BDNF as covariates. Next, we
are planning to compute regression analyses since we
hypothesize that the reduction of hippocampal activity
will be associated with memory performance change in
the pattern separation task and the VLMT. As explora-
tory analyses, we will investigate whether any variable
predicts successful neurofeedback; we will calculate the
association between Aβ levels in blood and hippocampal
activity; and we will identify the most successful down-
regulation strategies. For the prediction of successful
neurofeedback, we will apply machine learning methods
(e.g., cross-validated non-linear multivariate classifica-
tion) to obtain the most important features.
Sample size calculation
For the determination of sample size, we used G*power
[32]. Since no study so far tried to downregulate hippo-
campal activity, we opted for the detection of at least a
small effect (i.e., cohen’s f = 0.25). This would require an
inclusion of n = 84 in total (that is, n = 21 in each group)
for a repeated measures design with 4 groups and 4
measurements (i.e., baseline, post-intervention, follow-
up 1, follow-up 2). We used the following criteria to cal-
culate sample size: ANOVA with repeated measure-
ments and between-within interactions, α err = 0.01, 1-
β = 0.99, number of groups = 4, number of measure-
ments = 4.
Data management
All data will be entered by the study team and stored
using Research Electronic Data Capture (REDCap),
hosted by the Clinical Trials Unit (CTU) Bern. The
study team is responsible for data management; data
monitoring will be done by an independent researcher
not involved in the study. We will record any spontan-
eously reported adverse events or other unintended ef-
fects of the intervention. An annual safety report will be
submitted once a year to the local Ethics Committee.
Study data will be stored on servers of Bern University,
stripped of personal information of the participants.
Unblinding will occur after all raw data have been trans-
ferred to the data analysis software. All computers will
be password-protected and encrypted. At the end of the
study, all personal data will be deleted. The procedures
comply with Swiss data privacy laws.
Discussion
This study will examine whether real-time fMRI neuro-
feedback can reduce hippocampal hyperactivity and
whether the reduction will lead to an improvement in
memory performance. This will extend former research
showing that a pharmacological reduction of excess hip-
pocampal activity in patients with MCI led to better
memory performance using a pattern separation task [7].
In contrast to medication, real-time fMRI neurofeedback
comes with considerably fewer risks or side effects [33].
In addition, it may give patients a sense of empower-
ment as they themselves tone down hyperactivity with-
out having to ‘depend on’ taking medication. So far, the
assessment of the effectiveness of downregulating the
hippocampus requires using a set-up including an MR
scanner. This study may provide insight into strategies
that participants have successfully used to regulate hip-
pocampal activity. It would be such strategies that may
be included in future cognitive intervention studies.
Klink et al. BMC Psychiatry           (2021) 21:87 Page 7 of 9
Should our study be successful, we will test whether
other participants could use such strategies for them-
selves or whether each person will need to develop their
own strategy. In the context of clinical use, only a few
training sessions may produce long lasting effects [34,
35].
One aspect that may likely influence our results is the
type of control group [28]. We opted for an active con-
trol rather than no feedback or yoked feedback; that is,
feedback is given on the activity of a control region. In
our view, only the comparison with an active control
group can confirm that the results are specific to feed-
back from hippocampal activity [16]. However, differ-
ences between groups might still be related to
differences in the perceived difficulty to regulate. We
will account for this by evaluating how difficult partici-
pants thought it was to regulate.
Since we will gather blood samples to assess Aβ levels,
we may also be able to replicate previous research in
healthy elderly individuals, or patients with MCI, that re-
ported higher levels of Aβ are associated with increased
hippocampal activity [7, 9]. We will extend prior re-
search by testing whether this association is also evident
using blood-derived Aβ levels. In addition, blood sam-
ples will be used for the determination of the genetic
variants of ApoE and BDNF. This will allow an explor-
ation of the association of gene status with hippocampal
hyperactivity, the ability to downregulate via neurofeed-
back, and the improvement in memory performance. Be-
sides the primary goal of reducing hippocampal
hyperactivity, we may also provide information as to
whether successful neurofeedback can be predicted by
variables extracted from questionnaires [27]. We expect
that participants who score high on mental imagery as
well as self-efficiency would benefit from the interven-
tion. Likewise, those with high scores on openness and
low scores on state/trait anxiety may be those who learn
fast from feedback.
One limiting factor of our study might be the single-
blind design. We will not inform the participants from
which area they will receive feedback; yet, investigators
will need to generate the ROI files and prepare the indi-
vidual neurofeedback setup. Thus, they will not be
blinded. In future studies, a double-blind protocol that
could be implemented by separating investigators whot
prepare the individual setup from investigators who in-
struct the participants would be desirable.
In sum, our study will provide insight into the efficacy
of real-time fMRI neurofeedback to downregulate hippo-
campal hyperactivity in patients with MCI due to AD. It
will further elucidate whether downregulation will lead
to memory improvement. Data extracted from question-
naires may help to identify factors that predict successful
neurofeedback.
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